Koyfin Home > Directory > Health Care > Akebia Therapeutics > Gross Margin

Akebia Therapeutics Gross Margin Chart (AKBA)

Akebia Therapeutics annual/quarterly Gross Margin from 2016 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Akebia Therapeutics Gross Margin for the quarter ending June 06, 2020 was $18m a 49.61% increase of 9m year over year
  • Akebia Therapeutics Gross Margin for the last 12 months ending June 06, 2020 was $15m a 161.45% increase of 25m year over year
  • Akebia Therapeutics Annual Gross Margin for 2019 was $8m a 615.66% increase of 49m from 2018
  • Akebia Therapeutics Annual Gross Margin for 2018 was $-41m a 32.87% decrease of -13m from 2017
  • Akebia Therapeutics Annual Gross Margin for 2017 was $-27m a -27,058.87% increase of 7,416m from 2016
Other Margins & Efficiency Metrics:
  • Akebia Therapeutics EBITDA Margin for the quarter ending December 12, 2018 was $-142m a 62.80% decrease of -89m year over year
  • Akebia Therapeutics Return on Capital % for the quarter ending December 12, 2018 was -149.67 a 74.14% decrease of -110.96 year over year
  • Akebia Therapeutics Return on Equity % for the quarter ending December 12, 2018 was -247.98 a 76.13% decrease of -188.78 year over year
View Chart On Koyfin

Quarterly AKBA Gross Margin Data

06/2020$18m
03/2020$-1m
12/2019$41m
09/2019$9m
06/2019$6m
03/2019$-25m
12/2018$-48m
09/2018$-33m
06/2018$-47m
03/2018$-34m

Annual AKBA Gross Margin Data

2019$8m
2018$-41m
2017$-27m
2016$-7,443m